At 44.6% CAGR, the North America Enzymatic DNA Synthesis Market is projected to be worth US$ 1,011.32 million by 2028, says Business Market Insights

According to Business Market Insights research, the North America enzymatic DNA synthesis market was valued at US$ 110.43 million in 2022 and is expected to reach US$ 1,011.32 million by 2028, registering a CAGR of 44.6% from 2022 to 2028. Surging number of product launches and rising prevalence of genetic disorders are the critical factors attributed to the North America enzymatic DNA synthesis market expansion. 

Advancements in medical technologies and an increase in investments in R&D by manufacturers have resulted in the launch of various modern systems for genetic and molecular biology studies. Companies in The North America enzymatic DNA synthesis market are involved in different product development activities.

• In November 2021, OriCiro Genomics Inc. launched the OriCiro Cell-Free Switching system.
• In June 2021, DNA Script commercially launched its SYNTAX platform with the first product—the SYNTAX System. This system is the first benchtop nucleic acid printer powered by enzymatic DNA synthesis (EDS) technology. The SYNTAX System is a fully integrated, automated printer that synthesizes 96 DNA oligos in parallel, each of length of up to 60 nucleotides, and delivers them ready for use in molecular biology and genomics workflows, eliminating the need for additional handling.
• In January 2021, Codex DNA, Inc. signed a strategic collaboration and licensing agreement with Pfizer to access and further develop the novel EDS technology of Codex DNA for its potential application in Pfizer’s mRNA-based vaccines and other biopharma products.

Such developments help end users meet the rising demand for technically advanced systems that can efficiently manage data and provide accurate results, thereby boosting the market growth.

On the contrary, high costs and complex procedures hurdles the growth of North America enzymatic DNA synthesis market.

Based on product type, the North America enzymatic DNA synthesis market is bifurcated into custom DNA synthesis and DNA library synthesis. The DNA library synthesis segment held 66.8% share of North America enzymatic DNA synthesis market in 2022, amassing US$ 73.72 million. It is projected to garner US$ 666.63 million by 2028 to expand at 44.3% CAGR during 2022–2028.

Based on application, the North America enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and others. The synthetic biology segment held 50.8% share of North America enzymatic DNA synthesis market in 2022, amassing US$ 56.13 million. It is projected to garner US$ 506.71 million by 2028 to expand at 44.3% CAGR during 2022–2028.  

Based on end user, the North America enzymatic DNA synthesis market is segmented into academic & research institutes, biotech & pharmaceutical companies, diagnostic laboratories, and others. The biotech & pharmaceutical companies segment held 49.7% share of North America enzymatic DNA synthesis market in 2022, amassing US$ 54.84 million. It is projected to garner US$ 496.17 million by 2028 to expand at 44.3% CAGR during 2022–2028.  

Based on country, the North America enzymatic DNA synthesis market has been categorized into the US, Canada, and Mexico.  Our regional analysis states that the US captured 84.8% share of North America enzymatic DNA synthesis market in 2022. It was assessed at US$ 93.61 million in 2022 and is likely to hit US$ 850.62 million by 2028, exhibiting a CAGR of 44.5% during the forecast period.  

Key players profiles in the North America enzymatic DNA synthesis market report Ansa Biotechnologies, Inc.; Camena Bio; DNA Script; GenScript Biotech Corporation; Molecular Assemblies; Synbio Technologies; Telesis Bio Inc; Touchlight; and Twist Bioscience, among others.

• Oct-2022, Codex DNA, Inc., a leader in automated multi-omic and synthetic biology solutions, announced a plan to change its Company name to Telesis Bio. The innovative and pioneering spirit, versatility, and power of the Company’s technologies have enabled them to expand its portfolio to include an array of tools for both synthetic biology and genomics applications, and to reflect the expansion, an initiative to a change name to Telesis Bio was taken.
• Oct-2022, Telesis Bio and Cellibre initiated work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp Digital-to-Biological Converter (DBC) instrument for fully automated manufacturing of on-demand CRISPR-Cas9 guide RNA (gRNA) for genome editing. By integrating Telesis Bio SOLA EDS technology directly onto its BioXp 9600 system, the BioXp DBC instrument empowers scientists with same-day design and build capabilities for their guide RNAs, without the need to order custom reagents

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com